NEW YORK (GenomeWeb) – MDx Health said today it has signed an agreement with The Netherlands' University Erasmus Medical Center (Erasmus MC) giving it exclusive worldwide rights to the use of a set of bladder cancer methylation biomarkers for clinical assay development in either the LDT or IVD setting.

The company also announced that it plans to present new top-line data on the liquid biopsy bladder cancer test it is developing with these markers at the World Congress on Urological Research meeting in September.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Lawmakers have asked four direct-to-consumer genetic testing companies to explain their privacy policies and security measures, according to Stat News.

The Trump Administration has proposed a plan to reorganize the federal government, the Washington Post reports.

In Science this week: genetic overlap among many psychiatric disorders, and more.

The Economist writes that an increasing number of scientific journals don't do peer review.